Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Appointment

9 Nov 2007 16:59

Avacta Group plc Board Appointment

Avacta Group plc ("Avacta" or the "Company"), which develops detection and analysis technology aimed at the biopharmaceutical, defence & security and clinical diagnostics markets, is pleased to announce the appointment of Russell Hodgetts to the Board of Directors, with effect from 10 July 2007.

Russell Winston Hodgetts, 36, has been Chief Operating Officer of Avacta since October 2005, and has a wealth of experience in strategic business development and group operations. Prior to joining Avacta he worked for Techtran Group Limited where he helped guide the commercialization and business development of companies created from University of Leeds research and intellectual property.

He currently oversees the development of the analytical services division of the Company in addition to being responsible for group operations.

Russell Hodgetts is the beneficial owner of 9,847,912 ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares"), representing approximately 1.27 per cent. of the issued share capital of the Company and 1,804,568 options to acquire Ordinary Shares at an exercise price of 2.25p per share.

He is also a director of Avacta Analytical Limited.

Russell Hodgetts was named Russell Beckett until family circumstances led to his name being changed when aged 11.

There are no other disclosures required by paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Professor Alastair Smith, Chief Executive, Avacta Group plc, commented:

"Russell has been an integral part of the development of Avacta over the past two years and his focus on continued growth has been central to the success of Avacta Analytical Ltd. We are pleased to welcome him to the Board and will continue to draw on his knowledge and drive to ensure that Avacta maintains its current path of development and innovation."

9 November 2007EnquiriesAvacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive WH Ireland Limited Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Limited Tel: 020 7562 4713 Henry Turcan/Michael Brennan Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk

AVACTA GROUP PLC
Date   Source Headline
23rd Apr 20249:43 amRNSBlock Listing Application to AIM
23rd Apr 20247:00 amRNSNotice of Results
22nd Apr 202412:14 pmRNSIssue of Equity and Total Voting Rights
9th Apr 20245:00 pmRNSAvacta Reports Data at the AACR Annual Meeting
8th Apr 20247:00 amRNSAVA6000 Abstract Release by AACR
28th Mar 20244:00 pmRNSInvestor Webinar
21st Mar 20247:00 amRNSUpdate on AVA6000 Phase 1a Clinical Trial Progress
18th Mar 20241:26 pmRNSResult of General Meeting
6th Mar 20247:00 amRNSAvacta Announces AVA6000 Poster at AACR
5th Mar 20247:00 amRNSResult of REX Retail Offer
29th Feb 20247:00 amRNSResult of Placing
28th Feb 20244:42 pmRNSProposed REX Retail Offer
28th Feb 20244:41 pmRNSProposed Fundraise to progress Therapeutics
16th Feb 20247:00 amRNSShare Incentive Plan/Issue of Equity
22nd Jan 202410:51 amRNSIssue of Equity and Total Voting Rights
19th Jan 20247:00 amRNSAppointment of Christina Coughlin
19th Dec 20237:00 amRNSAppointment of Chief Business Officer
13th Dec 20237:00 amRNSALS-6000-101 Phase 1a Study Data
4th Dec 20237:00 amRNSShareholder update to review AVA6000 Phase 1a data
27th Oct 20237:00 amRNSBlock Listing Six Monthly Return
23rd Oct 20231:30 pmRNSIssue of Equity and Total Voting Rights
18th Oct 20231:00 pmRNSBlock Listing Application to AIM
5th Oct 20237:00 amRNSAvacta to present at AACR-NCI-EORTC conference
28th Sep 20237:00 amRNSInterim Results for the Period Ending 30 June 2023
20th Sep 20232:00 pmRNSIssue of Equity and Total Voting Rights
20th Sep 20237:01 amRNSPeel Hunt Appointed as Joint Broker
20th Sep 20237:00 amRNSAppointment Dr.Christina Coughlin as a consultant
19th Sep 20237:00 amRNSSuccessful Completion of Sixth Dose Escalation
6th Sep 20237:00 amRNSNotice of Results
21st Jul 20233:00 pmRNSIssue of Equity and Total Voting Rights
28th Jun 202311:00 amRNSResult of Annual General Meeting
28th Jun 20237:00 amRNSAnnual General Meeting and Shareholder Event
21st Jun 20237:00 amRNSCompletion of Fifth Dose Escalation in AVA6000
19th Jun 20237:01 amRNSDirector Appointment
19th Jun 20237:00 amRNSStatement regarding market speculation
8th Jun 20237:00 amRNSAGM and Shareholder Event Detailed Agenda
5th Jun 20237:00 amRNSSecond Milestone in AffyXell Joint Venture
2nd Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSAvacta acquires Coris Bioconcept
27th Apr 20237:00 amRNSBlock Listing Six Monthly Return
27th Apr 20237:00 amRNSFirst Patient Dosed in the US in AVA6000 Phase 1
25th Apr 20237:00 amRNSPreliminary Results
21st Apr 20232:49 pmRNSIssue of Equity and Total Voting Rights
17th Apr 20237:00 amRNSAVA3996 data poster presented at AACR
6th Apr 20237:00 amRNS1st US Clinical Investigator AVA6000 Sites Opened
5th Apr 20237:00 amRNSFirst Patient Dosed in Fifth Cohort of AVA6000
3rd Apr 20237:00 amRNSNotice of Results and Investor Presentation
27th Mar 20237:00 amRNSAVA3996 data poster presentation at AACR
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank
23rd Feb 20237:00 amRNSAvacta Therapeutics Division Science Day

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.